Quadratus Lumborum Block for Abdominoplasty

Quadratus Lumborum Block for Perioperative Analgesia in Patients Treated With Abdominoplasty: A Randomised Controlled Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02949778

Enrollment

Registered

2016-10-31

Start date

2016-11-07

Completion date

2017-12-13

Last updated

2017-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominoplasty, Pain, Postoperative

Brief summary

Double blinded, randomized, controlled, phase IV intervention trial. Both groups will receive a quadratus lumborum Block (QL), using ropivacaine 3.75 mg/mL in the intervention group, and sterile sodium chloride in the control group. The aim of study is to investigate the effect of a QL Block on the perioperative pain during postbariatric abdominoplasty.

Interventions

PROCEDUREQL-block

Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied

DRUGRopivacaine

Ropivacaine 3.75mg/ml administered in QL-block as active treatment

DRUGSodium Chloride

Sodium chloride 9mg/mL administered in QL-Block as placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists Physical Classification Status (ASA) I-II * Age 18 to 64 * Weight above or equal to 60 kg * Scheduled for post-bariatric surgery with standard full abdominoplasty performed by Dr Frøyen * Patient is expected able to cooperate during the treatment and follow up. * Signed informed consent obtained and documented according to the International Conference on Harmonization (ICH) good clinical practice (GCP), and national/local regulations.

Exclusion criteria

* A history of anaphylactic shock * Cardiovascular disease other than hypertension and/or hyperlipidemia * Known allergy to ropivacaine or morphine * A history of chronic pain * Psychiatric comorbidity * Scheduled opioid pain medication or neuroleptic drugs * Coagulation disorders or treatment with platelet inhibitors * Pregnancy or breastfeeding * Treatment with class III antiarrhythmics, sertindole, ziprasidone, amisulpride, ceritinib, hydroxyzine, fluvoxamine * Any medical contraindication to the study intervention by the attending anaesthetist or surgeon (to be specified in screening form).

Design outcomes

Primary

Measure	Time frame	Description
Opioid consumption	24 hours	total opioid consumption the first 24 postoperative hours

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026